サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1424096

ビグアナイド市場、シェア、規模、動向、産業分析レポート：タイプ別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

Biguanides Market Share, Size, Trends, Industry Analysis Report, By Type (Metformin, Phenformin, Others); By Distribution Channel; By Region; Segment Forecast, 2024- 2032

出版日
ページ情報
英文 116 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.08円
ビグアナイド市場、シェア、規模、動向、産業分析レポート：タイプ別、流通チャネル別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年01月24日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、ビグアナイドの世界市場規模は2032年までに61億9,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

現在進行中の取り組みは、製剤の革新、併用療法の探求、糖尿病治療におけるビグアナイド薬の用途拡大に重点を置いています。臨床的有効性、安全性、患者の転帰を向上させるための取り組みは、新規ドラッグデリバリーシステムや製剤の探求に表れています。また、ビグアナイド薬の治療領域を拡大するため、血糖コントロール以外の心代謝系への潜在的な有用性についても調査を行っています。製薬企業と学術機関の共同研究は技術革新を推進し、抗糖尿病治療のダイナミックな展望の中でビグアナイド薬の持続的な意義に貢献する継続的な研究を確実なものにしています。

テレヘルスの統合は、ビグアナイド市場の成長の原動力です。糖尿病管理が個別化ケアに向かって進化するにつれて、遠隔医療プラットフォームはより良い転帰のために遠隔患者モニタリングを合理化します。血糖値と服薬アドヒアランスのリアルタイム追跡は、特に糖尿病治療におけるビグアナイド薬の有効性を高める。バーチャル診察は、投薬レジメンの迅速な調整を可能にし、患者の関与を促進します。この統合は患者ケアを改善するだけでなく、糖尿病管理の進行中の研究のための貴重なデータにも貢献します。遠隔医療が提供する利便性は患者のコンプライアンスを向上させ、ビグアナイド薬の需要を煽り、市場拡大を促進します。

患者中心の製剤がビグアナイド市場の拡大を促進しています。個別化ヘルスケアのトレンドに沿った、徐放性オプションを含むこれらのオーダーメイド製剤は、ビグアナイド薬の魅力と有効性を高めています。副作用を最小限に抑え、投与レジメンを簡素化することで服薬アドヒアランスを高め、患者の快適さとコンプライアンスを優先します。満足度と服薬アドヒアランスの向上は、治療成果を最適化するだけでなく、ビグアナイド薬の市場望ましさを高めています。

併用療法は、ビグアナイド薬と他の治療クラスとの相乗効果を探ることで、ビグアナイド市場の成長を後押ししています。この研究開発は、治療効果を高める新たな機会を提供します。ビグアナイド薬とインスリン感作薬のような補完薬を組み合わせることで、血糖コントロールの改善と副作用の最小化が期待できます。この戦略は、糖尿病の多面的な性質に取り組むだけでなく、患者の治療選択肢を多様化させる。先駆的な併用療法に投資する製薬企業は、進化する糖尿病管理の展望を活用するために戦略的なポジションを確立し、包括的でカスタマイズされたソリューションでビグアナイド市場を前進させています。

ビグアナイド市場レポートハイライト

2023年、メトホルミンは有効性、安全性、手頃な価格により大きな市場シェアを占めました。

2023年、小売薬局セグメントは、患者にとって便利なアクセスと広範な入手可能性により、大きな収益シェアを占めました。

2023年には、糖尿病患者の増加と高齢化により北米地域が世界市場を独占しました。

市場は、AstraZeneca、Bayer AG、Boehringer Ingelheim、Dr. Reddy's Laboratories、Eli Lilly and Company、GlaxoSmithKline、Pfizer Inc.

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のビグアナイド市場に関する洞察

  • ビグアナイド市場- 業界スナップショット
  • ビグアナイド市場力学
    • 促進要因と機会
      • ファーストライン治療は製品の需要を刺激すると予測されています
      • 2型糖尿病の急増が市場の成長を促進すると予想される
    • 抑制要因と課題
      • 副作用の蔓延は市場の成長を妨げる可能性が高い
  • PESTLE分析
  • ビグアナイドの業界動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界のビグアナイド市場、タイプ別

  • 主な調査結果
  • イントロダクション
  • メトホルミン
  • フェンホルミン
  • その他

第6章 世界のビグアナイド市場、流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 小売薬局
  • 病院薬局
  • その他

第7章 世界のビグアナイド市場、地域別

  • 主な調査結果
  • イントロダクション
    • ビグアナイド市場評価、地域、2019-2032
  • ビグアナイド市場-北米
    • 北米：ビグアナイド市場、流通チャネル別、2019-2032
    • 北米：ビグアナイド市場、タイプ別、2019-2032
    • ビグアナイド市場-米国
    • ビグアナイド市場- カナダ
  • ビグアナイド市場- 欧州
    • 欧州：ビグアナイド市場、流通チャネル別、2019-2032
    • 欧州：ビグアナイド市場、タイプ別、2019-2032
    • ビグアナイド市場- 英国
    • ビグアナイド市場- フランス
    • ビグアナイド市場- ドイツ
    • ビグアナイド市場- イタリア
    • ビグアナイド市場- スペイン
    • ビグアナイド市場- オランダ
    • ビグアナイド市場- ロシア
  • ビグアナイド市場- アジア太平洋
    • アジア太平洋：ビグアナイド市場、流通チャネル別、2019-2032
    • アジア太平洋：ビグアナイド市場、タイプ別、2019～2032年
    • ビグアナイド市場- 中国
    • ビグアナイド市場- インド
    • ビグアナイド市場- マレーシア
    • ビグアナイド市場- 日本
    • ビグアナイド市場- インドネシア
    • ビグアナイド市場- 韓国
  • ビグアナイド市場-中東およびアフリカ
    • 中東およびアフリカ：ビグアナイド市場、流通チャネル別、2019-2032
    • 中東およびアフリカ：ビグアナイド市場、タイプ別、2019-2032
    • ビグアナイド市場- サウジアラビア
    • ビグアナイド市場- アラブ首長国連邦
    • ビグアナイド市場- イスラエル
    • ビグアナイド市場- 南アフリカ
  • ビグアナイド市場-ラテンアメリカ
    • ラテンアメリカ：ビグアナイド市場、流通チャネル別、2019-2032
    • ラテンアメリカ：ビグアナイド市場、タイプ別、2019-2032
    • ビグアナイド市場- メキシコ
    • ビグアナイド市場- ブラジル
    • ビグアナイド市場- アルゼンチン

第8章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila
図表

List of Tables

  • Table 1 Global Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 2 Global Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 3 Biguanides Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 5 North America: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 7 U.S.: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 8 Canada: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 9 Canada: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 10 Europe: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Europe: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 12 UK: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 13 UK: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 14 France: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 15 France: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 16 Germany: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 Germany: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 18 Italy: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 19 Italy: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 20 Spain: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 21 Spain: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Russia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 25 Russia: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 28 China: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 China: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 30 India: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 31 India: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 34 Japan: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Japan: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 39 South Korea: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 44 UAE: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 45 UAE: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 46 Israel: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Israel: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 49 South Africa: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 51 Latin America: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Mexico: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 55 Brazil: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 57 Argentina: Biguanides Market, by Type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Biguanides Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Distribution Channel
  • Figure 7 Global Biguanides Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Type
  • Figure 9 Global Biguanides Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10 Biguanides Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Biguanides Market
目次
Product Code: PM4410

The global Biguanides market size is expected to reach USD 6.19 billion by 2032, according to a new study by Polaris Market Research. The report "Biguanides Market Share, Size, Trends, Industry Analysis Report, By Type (Metformin, Phenformin, Others); By Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Ongoing efforts focus on innovating formulations, exploring combination therapies, and expanding the applications of biguanides in diabetes care. The commitment to enhancing clinical efficacy, safety, and patient outcomes is evident in the exploration of novel drug delivery systems and formulations. Research also investigates potential cardiometabolic benefits beyond glycemic control, broadening the therapeutic scope of biguanides. Collaborations between pharmaceutical entities and academic institutions drive innovation, ensuring that ongoing research contributes to the sustained significance of biguanides in the dynamic landscape of antidiabetic therapies.

Telehealth integration is a driving force behind the growth of the biguanides market. As diabetes management evolves towards personalized care, telehealth platforms streamline remote patient monitoring for better outcomes. Real-time tracking of blood glucose levels and medication adherence enhances the efficacy of biguanides, particularly in diabetes treatment. Virtual consultations enable prompt adjustments to medication regimens, fostering patient engagement. This integration not only improves patient care but also contributes valuable data for ongoing research in diabetes management. The convenience offered by telehealth enhances patient compliance, fueling the demand for biguanides and propelling market expansion.

Patient-centric formulations are driving the expansion of the biguanides market. Aligned with the trend towards personalized healthcare, these tailored formulations, including extended-release options, boost the appeal and efficacy of biguanides. They enhance medication adherence by minimizing side effects and simplifying dosing regimens, prioritizing patient comfort and compliance. Improved satisfaction and adherence not only optimize treatment outcomes but also heighten the market desirability of biguanides.

Combination therapies are propelling biguanides market growth by exploring synergies between biguanides and other therapeutic classes. This research and development avenue offers novel opportunities for heightened treatment efficacy. By combining biguanides with complementary drugs like insulin sensitizers, there's potential for improved glycemic control and minimized side effects. This strategy not only tackles the multifaceted nature of diabetes but also diversifies treatment options for patients. Pharmaceutical companies investing in pioneering combination therapies strategically position themselves to leverage the evolving diabetes management landscape, advancing the biguanides market with comprehensive and tailored solutions.

Biguanides Market Report Highlights

In 2023, the metformin segment accounted for significant market share owing to efficacy, safety profile, and affordability.

In 2023, the retail pharmacy segment held significant revenue share owing to convenient access for patients and widespread availability.

In 2023, North America region dominated the global market due to rising diabetes cases, and an aging population.

The market is highly competitive owing to the existence of market players with a global presence, including AstraZeneca, Bayer AG, Boehringer Ingelheim, Dr. Reddy's Laboratories, Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc., and Sanofi among others.

Polaris Market Research has segmented the Biguanides market report based on type, distribution channel, and region:

Biguanides, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Metformin
  • Phenformin
  • Others

Biguanides, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Retail Pharmacy
  • Hospital Pharmacy
  • Others

Biguanides, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Biguanides Market Insights

  • 4.1. Biguanides Market - Industry Snapshot
  • 4.2. Biguanides Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. First-Line Treatment is projected to spur the product demand
      • 4.2.1.2. Surging prevalence of type 2 diabetes is expected to drive market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Prevalence of side effects is likely to impede the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Biguanides Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Biguanides Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Biguanides, by Type, 2019-2032 (USD Billion)
  • 5.3. Metformin
    • 5.3.1. Global Biguanides Market, by Metformin, by Region, 2019-2032 (USD Billion)
  • 5.4. Phenformin
    • 5.4.1. Global Biguanides Market, by Phenformin, by Region, 2019-2032 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global Biguanides Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Biguanides Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 6.3. Retail Pharmacy
    • 6.3.1. Global Biguanides Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Global Biguanides Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Biguanides Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Biguanides Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Biguanides Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Biguanides Market - North America
    • 7.3.1. North America: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.3.2. North America: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.3.3. Biguanides Market - U.S.
      • 7.3.3.1. U.S.: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.3.4. Biguanides Market - Canada
      • 7.3.4.1. Canada: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.4. Biguanides Market - Europe
    • 7.4.1. Europe: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.4.3. Biguanides Market - UK
      • 7.4.3.1. UK: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.4.4. Biguanides Market - France
      • 7.4.4.1. France: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.4.5. Biguanides Market - Germany
      • 7.4.5.1. Germany: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.4.6. Biguanides Market - Italy
      • 7.4.6.1. Italy: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.4.7. Biguanides Market - Spain
      • 7.4.7.1. Spain: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.4.8. Biguanides Market - Netherlands
      • 7.4.8.1. Netherlands: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.4.9. Biguanides Market - Russia
      • 7.4.9.1. Russia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.5. Biguanides Market - Asia Pacific
    • 7.5.1. Asia Pacific: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.5.3. Biguanides Market - China
      • 7.5.3.1. China: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.5.4. Biguanides Market - India
      • 7.5.4.1. India: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.5.5. Biguanides Market - Malaysia
      • 7.5.5.1. Malaysia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.5.6. Biguanides Market - Japan
      • 7.5.6.1. Japan: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.5.7. Biguanides Market - Indonesia
      • 7.5.7.1. Indonesia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.5.8. Biguanides Market - South Korea
      • 7.5.8.1. South Korea: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.6. Biguanides Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.6.3. Biguanides Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.6.4. Biguanides Market - UAE
      • 7.6.4.1. UAE: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.6.5. Biguanides Market - Israel
      • 7.6.5.1. Israel: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.6.6. Biguanides Market - South Africa
      • 7.6.6.1. South Africa: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.7. Biguanides Market - Latin America
    • 7.7.1. Latin America: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.7.3. Biguanides Market - Mexico
      • 7.7.3.1. Mexico: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.7.4. Biguanides Market - Brazil
      • 7.7.4.1. Brazil: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Biguanides Market, by Type, 2019-2032 (USD Billion)
    • 7.7.5. Biguanides Market - Argentina
      • 7.7.5.1. Argentina: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Biguanides Market, by Type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AstraZeneca
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bayer AG
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Boehringer Ingelheim
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bristol Myers Squibb
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Dr. Reddy's Laboratories
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Eli Lilly and Company
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. GlaxoSmithKline
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Lupin Pharmaceuticals, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Merck & Co., Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Novartis
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Pfizer Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Sanofi
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Sun Pharmaceutical Industries Ltd.
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Teva Pharmaceutical Industries Ltd.
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Zydus Cadila
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development